Can MannKind (MNKD) Still Be A Bargain On Cash Flow?

MannKind has had a rough stretch in 2026, with the share price down 37.5% year to date, which puts fresh focus on whether the current US$3.50 level lines up with what its cash flows can support. With revenue now more heavily influenced by the Furoscix ReadyFlow acquisition and new product approvals, the key issue for investors is how those changes filter through to the stock's intrinsic value based on its cash generation.

• The 37.5% year to date decline raises the stakes for anyone asking whether the market is now pricing MannKind purely on recent sentiment or on its long term cash producing ability.

• The reported 43% revenue growth, driven largely by Furoscix ReadyFlow and accompanied by expanded Afrezza labeling and a solid cash balance of US$111 million, may support different expectations around future cash flow scale, timing, and funding needs.

• What if you looked at MannKind through its sales instead? See what MannKind's 2.9x P/S says about the price.

The issue now is whether MannKind's current share price is consistent with its intrinsic value estimate based on the Discounted Cash Flow (DCF) calculation of its future cash flows.

If you want a wider set of ideas built around clear cash flow and valuation checkpoints, consider using a focused screener of 33 high quality undervalued stocks.

Is MannKind a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here is built on MannKind's future free cash generation rather than near term earnings optics. Latest twelve month free cash flow sits at a loss of $24.1 million, so the valuation leans heavily on expectations that coming years look very different from the recent past.

Analysts feeding into this DCF framework are assuming first a recovery and then growth in cash flows, with projected free cash flow turning positive and rising into the tens of millions of dollars over the next decade. Because those improving cash flows are discounted back and still point to an intrinsic value meaningfully above the current $3.50 share price, the gap suggests the market is putting a steep risk penalty on the story.

The 43% revenue growth tied to the Furoscix ReadyFlow deal and broader product approvals helps explain why the model builds in rising future cash, even as MannKind reported a GAAP net loss and continues to invest in its pipeline. That contrast between the DCF output and today's share price is what the detailed valuation is designed to clarify. Find out what MannKind could be worth using our Discounted Cash Flow (DCF) estimate.